Opinion|Videos|July 29, 2024
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Novel Iberdomide Regimen in RRMM
2
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
3
AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk
4
IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds
5